Boston Therapeutics Phase I Study Results Accepted for Publication
10 mai 2018 13h04 HE
|
Boston Therapeutics, Inc.
LAWRENCE, Mass., May 10, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics (OTCQB:BTHE) is pleased to announce the acceptance of the Phase I proof of concept study of the pharmacology of BTI-320 prior to...
Boston Therapeutics Corporate Call Transcript Posted
27 avr. 2018 12h01 HE
|
Boston Therapeutics, Inc.
LAWRENCE, Mass., April 27, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics Inc. (the “Company” or “BTI”) (OTCQB:BTHE), an innovator in the design, development and commercialization of novel...
Boston Therapeutics to Hold Business Update Conference Call Wednesday, April 18, 2018 at 5:00 p.m. ET
16 avr. 2018 11h36 HE
|
Boston Therapeutics, Inc.
LAWRENCE, Mass., April 16, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics Inc. (the “Company” or “BTI”) (OTCQB:BTHE), an innovator in the design, development and commercialization of novel...
Boston Therapeutics Announces Letter of Intent to Acquire Pennsylvania-based Medical Technology Associates II (MTA2)
12 avr. 2018 09h35 HE
|
Boston Therapeutics, Inc.
LAWRENCE, Mass., April 12, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics Inc. (the “Company” or “BTI”) (OTCQB:BTHE) is pleased to announce that it has entered into a non-binding letter of intent...
Boston Therapeutics Awarded Key European Patent
06 avr. 2018 09h00 HE
|
Boston Therapeutics, Inc.
LAWRENCE, Mass., April 06, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics (the “Company” or “BTI”) (OTCQB:BTHE) is pleased to announce that it has won a patent position argued with the European Patent...
Boston Therapeutics Engages Medical and FDA Experts: Launching New Strategic Initiatives
29 mars 2018 13h11 HE
|
Boston Therapeutics, Inc.
LAWRENCE, Mass., March 29, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics, an innovator in the design, development and commercialization of novel treatments for diabetes and its related complications,...
Boston Therapeutics Creates New Scientific Advisory Board
27 mars 2018 11h48 HE
|
Boston Therapeutics, Inc.
LAWRENCE, Mass., March 27, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics, an innovator in the design, development and early commercialization of novel therapeutics for the potential treatment of...
Boston Therapeutics Joins the Biotechnology Innovation Organization (BIO)
08 mars 2018 11h05 HE
|
Boston Therapeutics, Inc.
LAWRENCE, Mass., March 08, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics, Inc announces their new participation in MassBIO, an unparalleled network of innovative companies and industry thought...
Boston Therapeutics Announces New COO, Loraine V. Upham
20 févr. 2018 09h00 HE
|
Boston Therapeutics, Inc.
LAWRENCE, Mass., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics, Inc. announces that Loraine V. Upham will join the team to lead the US operations and drug development effort for the diabetes...
Boston Therapeutics Announces Strategic Acquisition of CureDM
13 févr. 2018 09h00 HE
|
Boston Therapeutics, Inc.
LAWRENCE, Mass., Feb. 13, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics, Inc. (Boston Therapeutics) announces the acquisition of CureDM Group Holdings, LLC (CureDM), adding a Phase 2-ready drug to...